1. Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells
   Eveline Gart et al, 2021, Biomedicines CrossRef
2. Inhibition of plasminogen suppresses fibrosis and macrophage foaming in a nonalcoholic steatohepatitis mouse model
   Yuki Tomonari et al, 2022, Fundamental & Clinical Pharmacology CrossRef
3. Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets
   Ralf-Peter Czekay et al, 2022, Cancers CrossRef
4. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
   Yajie Fu et al, 2022, Frontiers in Pharmacology CrossRef
5. Comparison of plasminogen activator inhibitor-1 levels in chronic hepatitis B patients with hepatic cirrhosis and without hepatic cirrhosis
   Andhika Kusuma Hamdany et al, 2022, Open Access Macedonian Journal of Medical Sciences CrossRef
6. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
   Machteld Sillen et al, 2021, International Journal of Molecular Sciences CrossRef
7. Association between Equol Production Status and Nonalcoholic Steatohepatitis
   Takemi Akahane et al, 2021, International Journal of Molecular Sciences CrossRef